Comment

  • 6 August 2019

    AbbVie and Myovant drugs both to face insurance scrutiny

    The reimbursement experience with AbbVie’s Orilissa (elagolix) in endometriosis-related pain is likely to spill over to Myovant Sciences’ relugolix, and both drugs’ use to control menstrual bleeding in uterine fibroids

Close
Close
Close

Go Top